Abstract: Isotonic lipid emulsion for use in the treatment of a number of diseases such as an acute heart ischemia, a brain ischemia or another organ damage which occurred on a day, where the treatment is applied by intravenous bolus injection which is repeated at time intervals during at least that day at which the disease occurred, the isotonic lipid emulsion comprising a 78 to 95% by weight of medium chain triglycerides and 5 to 22% by weight of a substance, said substance being either a fish oil, wherein the fish oil has an eicosapentaenoic acid content of from 20 to 50% by weight; or an eicosapentaenoic acid, or a docosapentaenoic acid, or a docosahexaenoic acid, or a combination of eicosapentaenoic acid, and/or docosapentaenoic acid, and/or docosahexaenoic acid.

Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.

Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.

Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.

Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.

Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicosapentaenoic acid (EPA) groups and/or docosahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.

Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.

Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt. -% of the acyl-groups of said diglycerides, are eicosapentaenoic acid (EPA) groups and/or docosahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.

Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt. -% of the acyl-groups of said diglycerides, are eicosapentaenoic acid (EPA) groups and/or docosahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.

Abstract: The present invention relates to a composition and method for rapidly modifying the fatty acid composition of cell membranes of organs and tissues, in particular to increase the amount of omega-3 fatty acids of cell membranes of organs and tissues by parenterally administering to the human or animal body a supply of fatty acids in the form of an isotonic lipid emulsion comprising fatty acid triglycerides.

Abstract: This invention provides compositions in the form of emulsions comprising pharmaceutical agents, triglycerides and emulsifiers. This invention also provides methods for delivering pharmaceutical agents to predetermined tissues comprising administering the instant compositions. This invention also provides methods of making the instant compositions.

Abstract: The present invention relates to a composition and method for rapidly modifying the fatty acid composition of cell membranes of organs and tissues, in particular to increase the amount of omega-3 fatty acids of cell membranes of organs and tissues by parenterally administering to the human or animal body a supply of fatty acids in the form of an isotonic lipid emulsion comprising fatty acid triglycerides.

Abstract: This invention provides compositions in the form of emulsions comprising pharmaceutical agents, triglycerides and emulsifiers. This invention also provides methods for delivering pharmaceutical agents to predetermined tissues comprising administering the instant compositions. This invention also provides methods of making the instant compositions.

Abstract: The present invention pertains to hydrolysis-optimized isotonic lipid emulsions comprising medium-chain triglycerides (MCT), vegetable oils and fish oil, as well as their use for parenteral nutritition.